Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Effect of Dabrafenib and/or Trametinib in Pediatric Patients
NCT03975829Phase 4Active, not recruiting
- Sponsor
- Novartis
- Start
- Nov 2019
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 4 trial of dabrafenib + trametinib, trametinib in diffuse astrocytoma, anaplastic astrocytoma (AA), astrocytoma, Oligodendroglioma (OG), anaplastic oligodendroglioma (AO), sponsored by Novartis. Started Nov 2019; status: active, not recruiting.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
diffuse astrocytomaanaplastic astrocytoma (AA)astrocytomaOligodendroglioma (OG)anaplastic oligodendroglioma (AO)
Beyond the preview
Go deeper on NCT03975829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03975829.